Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall
Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
Biogen vs Eli Lilly: Jim Cramer weighs in
Invezz
Shares of Biogen Inc (NASDAQ: BIIB) are down about 8.0% on Wednesday after the U.S. Medicare programme refused to cover for its..
-
Biogen tumbles after Medicare lays out Aduhelm coverage plan
SeattlePI.com
-
Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Business Insider
-
Medicare limits coverage of $28,000-a-year Alzheimer's drug
SeattlePI.com
-
Medicare plans to cover Biogen drug only for patients in clinical trials
bizjournals
Advertisement
More coverage
Medicare limits coverage Aduhelm, the $28,000-a-year Alzheimer's drug from Biogen
USATODAY.com
Aduhelm's initial yearly price of $56,000 led to the largest-ever increase, in dollars, for Medicare's monthly "Part B" premium for..